Compare · NMRA vs RLMD
NMRA vs RLMD
Side-by-side comparison of Neumora Therapeutics Inc. (NMRA) and Relmada Therapeutics Inc. (RLMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. NMRA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while RLMD focuses on Biotechnology: Pharmaceutical Preparations.
- RLMD is the larger of the two at $321.2M, about 5.2x NMRA ($61.9M).
- RLMD has been more active in the news (8 items in the past 4 weeks vs 5 for NMRA).
- NMRA has more recent analyst coverage (23 ratings vs 14 for RLMD).
- Company
- Neumora Therapeutics Inc.
- Relmada Therapeutics Inc.
- Price
- -
- -
- Market cap
- $61.9M
- $321.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 5
- 8
- Recent ratings
- 23
- 14
Relmada Therapeutics Inc.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
Latest NMRA
- Amendment: SEC Form SCHEDULE 13G/A filed by Neumora Therapeutics Inc.
- SEC Form 10-Q filed by Neumora Therapeutics Inc.
- Neumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Neumora Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Officer Aurora Daljit Singh exercised 176,060 shares at a strike of $0.72 and sold $269,967 worth of shares (176,060 units at $1.53) (SEC Form 4)
- SEC Form 4 filed by Officer Berns Paul L
- SEC Form 4 filed by Officer Duncan Jason
- SEC Form 4 filed by Officer Milligan Michael Lee
- SEC Form 4 filed by President & CEO Pinto Joshua
Latest RLMD
- Amendment: SEC Form SCHEDULE 13G/A filed by Relmada Therapeutics Inc.
- Relmada Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
- Relmada Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Relmada Therapeutics Inc.
- Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London
- Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
- Chief Financial Officer Shenouda Maged bought $843,990 worth of shares (200,000 units at $4.22), increasing direct ownership by 25% to 1,000,000 units (SEC Form 4)
- Chief Executive Officer Traversa Sergio bought $828,000 worth of shares (200,000 units at $4.14), increasing direct ownership by 15% to 1,500,000 units (SEC Form 4)